Stockreport

Chinook Therapeutics Announces First Patient Dosed in Phase 2 AFFINITY Basket Study of Atrasentan in Proteinuric Glomerular Diseases

Chinook Therapeutics, Inc.  (KDNY) 
PDF Data from Initial Patient Cohorts of Phase 2 AFFINITY Study Expected to be Reported in 2022 SEATTLE, April 07, 2021 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NA [Read more]